Subscribe
clu
clu / iStockphoto.com
24 May 2018Americas

Fed Circuit sides with district court in UCB win against generics

Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More on this story

Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?